Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b/2, open-label, multicenter, randomized clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PEGPH20 in combination with atezolizumab compared with the standard chemotherapy regimens in patients with previously treated, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer

Next Previous
Trial Profile

A phase 1b/2, open-label, multicenter, randomized clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PEGPH20 in combination with atezolizumab compared with the standard chemotherapy regimens in patients with previously treated, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Hyaluronidase (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Genentech

Most Recent Events

  • 26 Oct 2017 New trial record
  • 24 Oct 2017 According to a Halozyme Therapeutics media release, the study will be conducted in the U.S., as well as countries outside the U.S. The overall analysis plan includes a retrospective analysis of the HA-high population identified using the Ventana HA companion diagnostic assay.
  • 24 Oct 2017 According to a Halozyme Therapeutics media release, first gastric cancer patient has been dosed in the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top